Classical homocystinuria (HCU) is an inborn error of metabolism caused by loss of cystathionine β-synthase (CBS) activity with the concomitant buildup of homocysteine. In knockout (KO) mice, a mouse model of HCU, complete lack of CBS is neonatally lethal. Administration of OT-58, an enzyme therapy for HCU, during the first 5 weeks of life rescued KO mice survival by preventing liver disease. Here, we studied the impact of a long-term uninterrupted OT-58 treatment or its absence beyond the neonatal period on liver pathology and metabolism. Plasma and liver metabolites of KO mice on OT-58 treatment were substantially improved or normalized compared with those receiving vehicle. Increased plasma activities of alanine aminotransferase and aspartate aminotransferase of vehicle-injected KO mice suggested the progression of liver damage with age and lack of treatment. At 3 months of age, liver histology showed no signs of hepatopathy in both vehicle- and OT-58-treated KO mice. However, moderate to severe liver disease, characterized by steatosis, hepatocellular necroses, disorganized endoplasmic reticulum, and swollen mitochondria, developed in 6-month-old vehicle-injected KO mice. KO mice on OT-58 treatment remained asymptomatic and were indistinguishable from age-matched healthy controls. Long-term uninterrupted OT-58 treatment was essential to prevent severe liver disease in the KO mouse model of HCU.

Department of Pediatrics and Adolescent Medicine Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Department of Pediatrics University of Colorado Anschutz Medical Campus Aurora Colorado

Institute of Pathology Charles University 1st Faculty of Medicine and General University Hospital Prague Czech Republic

Orphan Technologies Ltd Rapperswil Switzerland

Zobrazit více v PubMed

Allen, R. H., Stabler, S. P., & Lindenbaum, J. (1993). Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism: Clinical and Experimental, 42, 1448-1460.

Anbu, A. T., Mercer, J., & Wraith, J. E. (2006). Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I. Journal of Inherited Metabolic Disease, 29(1), 230-231. https://doi.org/10.1007/s10545-006-0237-8

Arning, E., & Bottiglieri, T. (2016). Quantitation of S-adenosylmethionine and S-adenosylhomocysteine in plasma using liquid chromatography-electrospray tandem mass spectrometry. Methods in Molecular Biology, 1378, 255-262. https://doi.org/10.1007/978-1-4939-3182-8_27

Bublil, E. M., Majtan, T., Park, I., Carrillo, R. S., Hulkova, H., Krijt, J., … Kraus, J. P. (2016). Enzyme replacement with PEGylated cystathionine beta-synthase ameliorates homocystinuria in murine model. Journal of Clinical Investigation, 126(6), 2372-2384. https://doi.org/10.1172/JCI85396

Gaull, G. E., & Schaffner, F. (1971). Electron microscopic changes in hepatocytes of patients with homocystinuria. Pediatric Research, 5, 23-32.

Gaull, G. E., Sturman, J. A., & Schaffner, F. (1974). Homocystinuria due to cystathionine synthase deficiency: Enzymatic and ultrastructural studies. Journal of Pediatrics, 84, 381-390.

Goldblatt, J., Fletcher, J. M., McGill, J., Szer, J., & Wilson, M. (2016). Interruption of enzyme replacement therapy in Gaucher disease. South African Medical Journal, 106(6 Suppl 1), S79-S81. https://doi.org/10.7196/SAMJ.2016.v106i6.11002

Kruger, W. D. (2017). Cystathionine beta-synthase deficiency: Of mice and men. Molecular Genetics and Metabolism, 121(3), 199-205. https://doi.org/10.1016/j.ymgme.2017.05.011

Lin, N. C., Niu, D. M., Loong, C. C., Hsia, C. Y., Tsai, H. L., Yeh, Y. C., … Liu, C. S. (2012). Liver transplantation for a patient with homocystinuria. Pediatric Transplantation, 16(7), E311-E314. https://doi.org/10.1111/j.1399-3046.2012.01666.x

Maclean, K. N., Sikora, J., Kozich, V., Jiang, H., Greiner, L. S., Kraus, E., … Kraus, J. P. (2010). Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. Molecular Genetics and Metabolism, 101(2-3), 163-171. https://doi.org/10.1016/j.ymgme.2010.06.007

Majtan, T., Hulkova, H., Park, I., Krijt, J., Kozich, V., Bublil, E. M., & Kraus, J. P. (2017). Enzyme replacement prevents neonatal death, liver damage, and osteoporosis in murine homocystinuria. FASEB Journal, 31(12), 5495-5506. https://doi.org/10.1096/fj.201700565R

Majtan, T., Park, I., Carrillo, R. S., Bublil, E. M., & Kraus, J. P. (2017). Engineering and characterization of an enzyme replacement therapy for classical homocystinuria. Biomacromolecules, 18(6), 1747-1761. https://doi.org/10.1021/acs.biomac.7b00154

Morris, A. A., Kozich, V., Santra, S., Andria, G., Ben-Omran, T. I., Chakrapani, A. B., … Chapman, K. A. (2017). Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. Journal of Inherited Metabolic Disease, 40(1), 49-74. https://doi.org/10.1007/s10545-016-9979-0

Mudd, S. H., Levy, H. L., & Kraus, J. P. (2001). Disorders of transsulfuration. In C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle, B. Childs, K. Kinzler & B. Vogelstein (Eds.), The metabolic and molecular bases of inherited disease (8 ed., pp. 2007-2056). New York: McGraw-Hill.

Snyderman, S. E. (2006). Liver failure and neurologic disease in a patient with homocystinuria. Molecular Genetics and Metabolism, 87(3), 210-212. https://doi.org/10.1016/j.ymgme.2005.10.010

Walter, J. H., Wraith, J. E., White, F. J., Bridge, C., & Till, J. (1998). Strategies for the treatment of cystathionine β-synthase deficiency: The experience of the Willink biochemical genetics unit over the past 30 years. European Journal of Pediatrics, 157(Suppl 2), S71-S76.

Watanabe, M., Osada, J., Aratani, Y., Kluckman, K., Reddick, R., Malinow, M. R., & Maeda, N. (1995). Mice deficient in cystathionine β-synthase: Animal models for mild and severe homocyst(e)inemia. Proceedings of the National Academy of Sciences of the United States of America, 92, 1585-1589.

Yang, R., Qu, C., Zhou, Y., Konkel, J. E., Shi, S., Liu, Y., … Shi, S. (2015). Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T cell differentiation and maintain immune homeostasis. Immunity, 43(2), 251-263. https://doi.org/10.1016/j.immuni.2015.07.017

Yap, S., Boers, G. H., Wilcken, B., Wilcken, D. E., Brenton, D. P., Lee, P. J., … Naughten, E. R. (2001). Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: A multicenter observational study. Arteriosclerosis, Thrombosis, and Vascular Biology, 21(12), 2080-2085.

Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function

Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria